| Literature DB >> 9667971 |
P S Dragovich1, S E Webber, R E Babine, S A Fuhrman, A K Patick, D A Matthews, S H Reich, J T Marakovits, T J Prins, R Zhou, J Tikhe, E S Littlefield, T M Bleckman, M B Wallace, T L Little, C E Ford, J W Meador, R A Ferre, E L Brown, S L Binford, D M DeLisle, S T Worland.
Abstract
The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (kobs/[I]) ranging from 60 to 280 000 M-1 s-1 and antiviral EC50's which approach 0.15 microM. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (kobs/[I] = 800 000 M-1 s-1) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 microM). A 1.9 A crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-2 3CP is also detailed.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9667971 DOI: 10.1021/jm9800696
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446